Effectiveness of Botulinum Toxin A in Treatment of Hemiplegic Shoulder Pain: A Systematic Review and Meta-analysis
Hui-Min Xie,Ting-Ting Guo,Xuan Sun,Han-Xiao Ge,Xue-Dan Chen,Ke-Jia Zhao,Li-Ning Zhang
DOI: https://doi.org/10.1016/j.apmr.2020.12.010
IF: 4.06
2021-09-01
Archives of Physical Medicine and Rehabilitation
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>To evaluate the effectiveness of botulinum toxin A (BTX-A) in treatment of hemiplegic shoulder pain.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Data Sources</h3><p>PubMed, EMBASE, Elsevier, Springer, Cochrane Library, Physiotherapy Evidence Database, CNKI, and VIP were researched from the earliest records to September 1, 2020.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Study Selection</h3><p>Randomized controlled trials that compared shoulder BTX-A injections versus a control intervention in patients with a history of hemiplegic shoulder pain after stroke, were selected. Among the 620 records screened, 9 trials were included with 301 eligible patients.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Data Extraction</h3><p>Outcome data were pooled according to follow-up intervals (1, 2, 4 and 12 weeks), and the primary evaluation indices were pain reduction (visual analog scale score [VAS] ) and range of motion improvement (ROM). The second evaluation indices were upper limb functional improvement, spasticity improvement, and incidence of adverse events. Cochrane risk-of-bias was used to assess the methodological quality of studies by two evaluators, independently.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Data Synthesis</h3><p>Meta-analysis revealed a statistically significant decrease in the VAS score in the BTX group versus the control group at 1, 4, and 12 weeks postinjection (SMD = -0.91, 95% CI: -1.54–-0.27; SMD = -1.63, 95% CI: -2.51–-0.76; SMD = -1.96, 95% CI: -2.47–-1.44). Furthermore, the meta-analysis demonstrated a statistically significant increase in abduction at 1, 4, 12 weeks postinjection (SMD = 3.71, 95% CI: 0–7.41; SMD = 8.8, 95% CI: 2.22–15.37; SMD = 19.59, 95% CI: 9.05–30.13) and external rotation at 1, 2, 4 weeks postinjection (SMD = 5.67, 95% CI: 0.88–10.47; SMD = 9.62, 95% CI: 5.57–13; SMD = 6.89, 95% CI: 2.45–11.33) in the BTX group.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>BTX-A injection provided greater analgesic effects and increased shoulder abduction and external rotation ROM compared with steroid or placebo injection for the treatment of HSP.</p>
rehabilitation,sport sciences